Open AccessAcid citrate dextrose (acd) formula a as a new anticoagulant in the measurement of in vitro platelet aggregation
Author(s) -
Pignatelli Pasquale,
Pulcinelli Fabio M.,
Ciatti Filippo,
Pesciotti Marzia,
Sebastiani Silvia,
Ferroni Patrizia,
Gazzaniga Pier Paolo
Publication year - 1995
Publication title -
journal of clinical laboratory analysis
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.536
H-Index - 50
eISSN - 1098-2825
pISSN - 0887-8013
DOI - 10.1002/jcla.1860090211
Subject(s) - platelet , epinephrine , mean platelet volume , chemistry , in vitro , platelet aggregation , pharmacology , biochemistry , medicine
To evaluate whether the use of ACD Formula A may affect in vitro platelet function, blood samples were obtained from 21 healthy blood donors and anticoagulated in ACD (acid‐citrate dextrose, NIH Formula A), Na citrate 3.8%, and K 3 EDTA. Platelet count, mean platelet volume, and in vitro platelet aggregation were evaluated on each sample. No significant difference was observed in platelet count and mean platelet volume among the different samples. Conversely, the ACD treated platelets showed a higher reactivity to the agonists as demonstrated by a significant increase of the maximum percentages of aggregation induced by ADP, epinephrine, and collagen, as well as a significant decrease of secondary aggregation thresholds to ADP and epinephrine. In conclusion, it may be speculated that ACD Formula A is capable of better maintaining the intraplatelet signal transduction mechanisms during PRP preparation, thus improving the overall responsiveness of platelets.©1995 wiley‐Liss, inc.